465 related articles for article (PubMed ID: 24388202)
1. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis.
Koskas M; Uzan J; Luton D; Rouzier R; Daraï E
Fertil Steril; 2014 Mar; 101(3):785-94. PubMed ID: 24388202
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma.
Guillon S; Popescu N; Phelippeau J; Koskas M
Int J Gynaecol Obstet; 2019 Sep; 146(3):277-288. PubMed ID: 31197826
[TBL] [Abstract][Full Text] [Related]
3. [Fertility-sparing management of endometrial cancer and atypical hyperplasia].
Gonthier C; Trefoux-Bourdet A; Luton D; Koskas M
Gynecol Obstet Fertil Senol; 2017 Feb; 45(2):112-118. PubMed ID: 28368791
[TBL] [Abstract][Full Text] [Related]
4. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
[TBL] [Abstract][Full Text] [Related]
5. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
6. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
7. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer.
Gonthier C; Walker F; Luton D; Yazbeck C; Madelenat P; Koskas M
Gynecol Oncol; 2014 Apr; 133(1):33-7. PubMed ID: 24680589
[TBL] [Abstract][Full Text] [Related]
8. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management.
Vaugon M; Peigné M; Phelippeau J; Gonthier C; Koskas M
Reprod Biomed Online; 2021 Sep; 43(3):495-502. PubMed ID: 34315696
[TBL] [Abstract][Full Text] [Related]
9. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
[TBL] [Abstract][Full Text] [Related]
10. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
12. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
13. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
[TBL] [Abstract][Full Text] [Related]
14. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments.
Yin J; Ma S; Shan Y; Wang Y; Li Y; Jin Y; Pan L
Cancer Prev Res (Phila); 2020 Apr; 13(4):403-410. PubMed ID: 32015095
[TBL] [Abstract][Full Text] [Related]
16. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
Gunderson CC; Fader AN; Carson KA; Bristow RE
Gynecol Oncol; 2012 May; 125(2):477-82. PubMed ID: 22245711
[TBL] [Abstract][Full Text] [Related]
17. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia.
Wang Y; Zhou R; Wang H; Liu H; Wang J
Int J Gynecol Cancer; 2019 May; 29(4):699-704. PubMed ID: 30826750
[TBL] [Abstract][Full Text] [Related]
18. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience.
Shikeli S; Gowri V; Rawahi TA
JBRA Assist Reprod; 2020 Oct; 24(4):466-469. PubMed ID: 32569453
[TBL] [Abstract][Full Text] [Related]
19. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia.
Ichinose M; Fujimoto A; Osuga Y; Minaguchi T; Kawana K; Yano T; Kozuma S
Int J Gynecol Cancer; 2013 Feb; 23(2):288-93. PubMed ID: 23314282
[TBL] [Abstract][Full Text] [Related]
20. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
He Y; Wang Y; Zhou R; Wang J
Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
